Microbiotica

Microbiotica Announces Positive Results from its Phase 1b Trial (MELODY-1) of MB097, a Precision Microbiome Co-Therapy in Advanced Melanoma

MB097 used in combination with MSD’s anti-PD-1 therapy, KEYTRUDA (pembrolizumab) 18 May 2026 — Cambridge, UK — Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), announces that all primary and secondary objectives were met in its advanced melanoma (MELODY-1) Phase 1b trial. MELODY-1 was an…

Microbiotica to Present Positive Update on Manufacturing Progress of its Live Biotherapeutic Products for Forthcoming Melanoma and Ulcerative Colitis Clinical Studies

9 July 2024, Cambridge United Kingdom – Microbiotica, a biopharma company developing a pipeline of orally-delivered precision microbiome medicines called live biotherapeutic products (LBPs), announces that Adam Wilkinson, its vice president of pre-clinical development, will present an overview of the company’s successful product manufacturing campaigns ahead of its forthcoming melanoma and ulcerative colitis clinical studies…
Microbiotica Limited Chesterford Research Park Little Chesterford Cambridge CB10 1XL UK

+44 7801 480569